Androgen receptor (AR) signaling remains the central molecular driver of prostate cancer, sustaining tumor growth and contributing to the development of resistance to current therapies.
Kintor Pharmaceutical Ltd.’s topical androgen receptor antagonist, pyrilutamide (KX-826), met the primary endpoint in a pivotal phase III trial in male androgenetic alopecia, and the company will soon file an NDA with China’s National Medical Products Administration.
Kintor Pharmaceutical Ltd.’s topical androgen receptor antagonist, pyrilutamide (KX-826), met the primary endpoint in a pivotal phase III trial in male androgenetic alopecia, and the company will soon file an NDA with China’s National Medical Products Administration.
Researchers from the Institute of Medicinal Biotechnology in China reported the preclinical characterization of a series of benzene sulfonamide derivatives developed as androgen receptor (AR) antagonists.
Prostate cancer, the second most frequent malignancy among men worldwide, can be treated using various antagonists of the androgen receptor, but many patients develop resistance within 18-24 months, and the resistance can block efficacy of not only the first-line antagonist but later-line antagonists as well. Therefore next-generation antagonists based on novel scaffolds are urgently needed.
Shanghai Jemincare Pharmaceuticals Co. Ltd. has identified androgen receptor antagonists reported to be useful for the treatment of cancer, alopecia, acne, hirsutism, polycystic ovary syndrome, precocious puberty, spinal and bulbar muscle atrophy, and age-related macular degeneration.
Haihe Biopharma Co. Ltd. has described androgen receptor antagonists reported to be useful for the treatment of acne, androgenic alopecia, breast and prostate cancer, benign prostatic hyperplasia, hidradenitis suppurativa, hirsutism and prostatitis.
The University of California and the US Department of Veterans Affairs have patented androgen receptor (AR) antagonists reported to be useful for the treatment of prostate cancer.
Shanghai Jemincare Pharmaceuticals Co. Ltd. has disclosed phosphorus-containing compounds acting as androgen receptor antagonists reported to be useful for the treatment of cancer, alopecia, acne, hirsutism and more.
